Adrenal metastasis as first presentation of hepatocellular carcinoma by Tsalis, Kostas et al.
BioMed  Central
Page 1 of 6
(page number not for citation purposes)
World Journal of Surgical Oncology
Open Access Case report
Adrenal metastasis as first presentation of hepatocellular 
carcinoma
Kostas Tsalis*, Emmanouil Zacharakis, Nikolaos Sapidis, Ioannis Lambrou, 
Evangelos Zacharakis and Dimitrios Betsis
Address: 4th Surgical Department, Aristotle University of Thessaloniki, 'G. Papanikolaou' General Regional Hospital, Exohi, Thessaloniki 57010, 
Greece
Email: Kostas Tsalis* - Ctsalis@med.auth.gr; Emmanouil Zacharakis - manoszacharakis@hotmail.com; Nikolaos Sapidis - 29-ca-@otenet.gr; 
Ioannis Lambrou - Lambrou1@otenet.gr; Evangelos Zacharakis - manoszacharakis@hotmail.com; Dimitrios Betsis - Ctsalis@med.auth.gr
* Corresponding author    
Abstract
Background: Metastases from hepatocellular carcinoma (HCC) can be found in the lung and
adrenal gland. We report case of a patient who presented with adrenal metastasis as the first
clinical manifestation of HCC.
Case presentation: A patient was referred for surgical treatment for a tumor in retro-peritoneal
space. The computerized tomography (CT) scan revealed a mass originating from the left adrenal
gland. The patient underwent left adrenalectomy and the exploration of abdominal cavity did not
reveal any other palpable lesions. Histologically, the resected lesion was a poorly differentiated
metastatic tumor from HCC. Seven months later patient was readmitted complaining of cachexia,
icterus, and significant weight loss. CT scan revealed hyperdense lesions of the liver
Conclusion: HCC may have atypical presentations like in present case. Fine needle aspiration/tru-
cut® biopsy might be useful in the investigation of an accidentally discovered adrenal mass
regardless of the size and can lead to the detection of a primary tumor.
Background
Metastases from hepatocellular carcinoma (HCC) can be
found in the lung and adrenal gland [1]. It has been
reported that adrenal metastases from HCC are found in
8.4 % of autopsy cases, being the second most common
site of metastasis after the lung [1]. Recent advances in
diagnostic techniques and therapeutic methods have con-
tributed to an improved prognosis for patients with HCC
[2].
Despite the fact that adrenal metastases from HCC are
well documented, it is rare to have adrenal metastasis as
the first clinical manifestation.
Case presentation
A 76 year old man was refferd from a District Hospital for
further treatment of a tumor in retro-peritoneal space,
originating from the left adrenal gland.
The patient was admitted to the District Hospital for
investigation of macroscopic haematuria and lumbar pain
during the last 48 hours. He had a past medical history of
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hypertension and hepatitis B. The laboratory investiga-
tions revealed hypercalcaemia and in an abdominal ultra-
sound scan (US), a mass was detected in the
retroperitoneal space close to the left kidney. Then a Com-
puted Tomography (CT) scan with contrast was per-
formed which revealed an enhancing mass, 10 cm in
diameter, between the pancreas and the left kidney origi-
nating from the left adrenal gland. No other pathological
findings from intra or extra-peritoneal organs were identi-
fied (Figure 1). The serum alpha-fetoprotein (AFP) con-
centration was 75.6 ng/ml (normal range: 0–10 ng/ml)
and C19-9 concentration 37.6 ng/ml, while the liver func-
tion tests were normal.
After his admission to our Department, the patient was
tested for underlying hormonally active tumor by low
dose (1 mg) overnight dexamethasone suppression test
and a 24-hour urine collection for catecholamines, corti-
sol, 17-ketosteroids, metanephrines and vanillylmandelic
acid. As the patient was hypertensive, plasma aldosterone
and plasma rennin were also tested. None of the tests indi-
cated a functional adrenal tumor. The patient was under
surveillance due to hepatitis B and had been subjected to
AFP measurement and US scan 2, 8 and 14 months prior
to his admission (AFP: 65, 69 and 60 ng/ml respectively).
Regarding the facts that there was not remarkable increase
in the AFP level during the last 14 months, the multiple
US scans were negative and the CT scan on admission did
not reveal any intrahepatic lesion, HCC was not consid-
ered in our patient.
With a presumptive diagnosis of a non-functional adrenal
tumor, the patient underwent left adrenalectomy through
a left Köcher incision. The exploration of the other intra-
peritoneal organs did not reveal any other palpable
lesions while the liver was found to be cirrhotic during the
operation. The resected lesion was a firm elastic mass
measuring 11.5 cm by 7.5 cm (Figure 2). The postopera-
tive course was uneventful and the patient was discharged
on day 7. Histologically, the resected lesion was a poorly
differentiated metastatic HCC with trabecullar patterns.
The patient was then informed of the findings and con-
tacted for readmission, further investigation and adjuvant
therapy. However, despite our repeated attempts, the
patient refused to be subjected to any further investigation
or treatment.
Seven months later patient presented with cachexia,
icterus, abdominal discomfort and significant weight loss
(more than 10 % of body weight). The serum alpha-feto-
protein (AFP) concentration was 1620.5 ng/ml and the
serum bilirubin 5.4 mg/dL. CT scan revealed hyperdense
lesions of the liver (Figure 3). Even though Trans-Arterial
Embolization (TAE) was then performed, the serum AFP
concentration showed persistently elevation to 3543 ng/
ml one month later, and the patient died 3 months after
readmission due to rapidly progressive liver failure.
Discussion
Adrenal gland is the second most common site of hema-
togenous spread from HCC after the lung and has been
found in up to 8.4% of cases at autopsy [1]. It is not clear
why the adrenal gland has a greater incidence of metas-
tases from HCC than other organs, however, it is claimed
that the most likely route of metastases is the arterial
spread via the aorta [3].
Adrenal metastasis in HCC are seldom treated by surgery
as by the time they are diagnosed, the tumor is usually far
advanced and the patients present with locally advanced
primary hepatic lesions and poor liver function [4]. In our
case, the adrenal metastasis was the first clinical presenta-
tion of HCC and till that time the primary tumor was not
apparent on CT or US scan thus making it possible for us
to resect the adrenal tumor.
At present, there is a wide variation in therapeutic modal-
ities for adrenal metastases from HCC, as the tumor is
usually accompanied by other distant or intrahepatic
metastases and the patients are not always fit for a major
operation. Trans-arterial embolization has been used for
non-surgical treatment of these tumors. Sakamoto et al [5]
CT scan showing left adrenal gland tumor 10 cm in diameter,  having homogenous intensity Figure 1
CT scan showing left adrenal gland tumor 10 cm in diameter, 
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stated that a complete TAE is difficult because the adrenal
gland has three feeding arteries. Taniai et al [6] reported
that despite the fact that adrenalectomy is the most effec-
tive way to control adrenal metastases from HCC, TAE is
chosen as treatment of choice when the patients' perform-
ance status is too poor to tolerate an operation. Finally,
ultrasound-guided percutaneous ethanol injection ther-
apy (PEIT) is claimed to have technical difficulties and
carry the additional risk of tumor seeding through the
needle tract or bleeding from the punctured tumor [5,7].
However, Momoi et al [8] in a retrospective study of 20
patients treated for adrenal metastasis of HCC by various
methods reported that PEIT shows good results for small
adrenal metastasis. In our case, adrenalectomy was our
first option as the patient's condition allowed an opera-
tion and the diagnosis of a primary HCC had not been
established by the CT scan imaging, the serum AFP con-
centration and the liver function tests during the preoper-
ative period.
Recent advances in diagnostic imaging techniques such as
CT scan or Magnetic Resonance Imaging (MRI) have sig-
nificantly improved the ability of detection of liver lesions
while there have not been any reports of metastatic lesions
in the adrenal gland without clinical or CT scan finding of
the primary HCC [6]. Recently, Iannaccone et al [9]
reported that despite the use of updated equipment and
optimized study protocols, CT scan has poor sensitivity
for the detection of hepatocellular carcinoma. This is in
contrast to Bartolozzi et al [10] who reported that Lipi-
odol-CT scan is the single most sensitive examination to
detect small nodules of HCC, having a specificity of 86%
compared to 62% for conventional CT scan. Similarly,
Kitagawa et al [4] stated that MRI is more useful than CT
scan for the assessment of primary liver tumors. In our
case, patient preference not to be subjected to further
investigation immediately after the histological diagnosis
of metastatic HCC, prevented further imaging of the liver
with either MRI and/or Lipiodol-CT scan, in order to
The resected adrenal mass was 11.5 cm by 7.5 cm in size Figure 2
The resected adrenal mass was 11.5 cm by 7.5 cm in size.World Journal of Surgical Oncology 2005, 3:50 http://www.wjso.com/content/3/1/50
Page 4 of 6
(page number not for citation purposes)
identify and locate the primary lesion which may have
been resectable at this stage. Moreover, our patient had an
abdominal ultrasound scan which did not reveal any int-
rahepatic lesion. The combination of US and CT scan
appears to have a sensitivity of 86% in detecting hepato-
cellular carcinoma [10]. We assume that the intrahepatic
lesion might have been a small one at that stage making
difficult its detection by conventional imaging.
The review of the literature revealed a few reports of
metastases being the initial presentation of HCC. Ascani et
al [11] reported a case of an osteolytic vertebral lesion to
be the first manifestation, which was clinically silent until
then. Similar reports with an initial finding of skeletal
metastases from clinically silent HCC have been also pre-
sented by Omura et al [12] and Yang et al [13] who
reported two cases. Besides, Baba et al [14] reported histo-
logical confirmation of HCC with right atrial metastasis to
be the primary clinical manifestation. Finally, Gilsanz et al
[15] reported a case of a patient who had a mass in the
gluteal region for three years that turned out to be a metas-
tasis of HCC. To our knowledge, this is the first case with
adrenal metastasis as first presentation and subsequent
histological confirmation of a silent HCC.
Hyperdense lesions of the liver in the arterial phase of the CT scan Figure 3
Hyperdense lesions of the liver in the arterial phase of the CT scan.World Journal of Surgical Oncology 2005, 3:50 http://www.wjso.com/content/3/1/50
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Incidentally discovered adrenal masses (incidentalomas)
are fairly common, but the correct management of such
lesions is not well established. Every patient with an inci-
dentally discovered adrenal mass has to be investigated to
detect malignancy and subtle hormonal overproduction
in order to select the cases for surgical treatment. There are
reports mentioning the value of fine needle aspiration/cut
biopsy in differentiation of benign and malignant inci-
dentalomas, stating that they are more sensitive than CT
and MRI scan while size criteria are of little value [16].
Other authors recommend the use of FNA cytology in all
patients with incidentalomas of more than 2 cm in size
[17]. However, it is well documented that regardless of the
endocrine status of an adrenal mass, the mass size espe-
cially if it is greater than 6 cm is a parameter associated
with malignancy [18,19]. Lesions greater than 6 cm in
diameter have an approximate risk of 35% for malignancy
[20]. Thus, many authors suggest that for prophylactic
purposes, surgery should be considered in all patients
with tumors greater than 6 cm [21-23]. This was also our
policy as the adrenal mass in our patient was non func-
tional and its size was greater than 6 cm suggesting high-
risk of malignancy. However, if fine needle aspiration/tru-
cut® biopsy was performed, the primary tumor, which was
obscure until then, might not have been missed until after
the operation when the pathology report was available.
Conclusion
Atypical presentations of HCC are rare, adrenal metastasis
can be the first clinical manifestation of the disease. Fine
needle aspiration/needle biopsy might be useful in the
investigation of an accidentally discovered adrenal mass
regardless of the size as it can lead to the detection of a pri-
mary tumor, in case of metastatic disease, that is silent at
this stage.
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